Payment overview · 2025
General Payments
$121.64
6 reported records · 4 companies
Healthcare provider profile · identity verified
Matthan Jackson, DO
Allopathic & Osteopathic Physicians|Family Medicine · ELKINS, WV · NPI 1194170571
Verified facts
What the public records show
CMS Open Payments records show Matthan Jackson, DO received $121.64 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.68 | 31.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.96 | 30.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.75 | 22.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.25 | 15.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.64 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 80 |
| Mirtazapine | Mirtazapine | 306 | 35 |
| Gabapentin | Gabapentin | 299 | 40 |
| Furosemide | Furosemide | 284 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 46 |
| Omeprazole | Omeprazole | 273 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 51 |
| Eliquis | Apixaban | 198 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 40 |
| Lisinopril | Lisinopril | 160 | 39 |
| Sertraline Hcl | Sertraline Hcl | 148 | 25 |
| Metformin Hcl | Metformin Hcl | 136 | 35 |
| Sucralfate | Sucralfate | 136 | 25 |
| Potassium Chloride | Potassium Chloride | 122 | 25 |
| Buspirone Hcl | Buspirone Hcl | 118 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 16 |
| Divalproex Sodium | Divalproex Sodium | 112 | 22 |
| Donepezil Hcl | Donepezil Hcl | 112 | 23 |
| Tramadol Hcl | Tramadol Hcl | 109 | 22 |
| Lorazepam | Lorazepam | 102 | 28 |
| Montelukast Sodium | Montelukast Sodium | 101 | 19 |
| Famotidine | Famotidine | 96 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 27 |
| Januvia | Sitagliptin Phosphate | 90 | 12 |
| Cefdinir | Cefdinir | 87 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Xarelto | Rivaroxaban | 87 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 19 |
| Carvedilol | Carvedilol | 81 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | 12 |
| Trazodone Hcl | Trazodone Hcl | 76 | 11 |
| Lactulose | Lactulose | 74 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 13 |
| Baclofen | Baclofen | 73 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 12 |
| Levetiracetam | Levetiracetam | 69 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 25 |
| Memantine Hcl | Memantine Hcl | 68 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 12 |
| Glipizide | Glipizide | 65 | 19 |
| Jardiance | Empagliflozin | 65 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 12 |
| Losartan Potassium | Losartan Potassium | 64 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 48 |
| Fentanyl | Fentanyl | 56 | suppressed |
| Spironolactone | Spironolactone | 56 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 12 |
| Simvastatin | Simvastatin | 49 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 24 |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Prednisone | Prednisone | 39 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Ozempic | Semaglutide | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 21 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Azathioprine | Azathioprine | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 11 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Nystatin | Nystatin | 18 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.64 · 6 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, Cologuard Collection Kit, GVOKE HYPOPEN, Ozempic, PREVNAR 20, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error